Digital Breast Tomosynthesis Versus Digital Mammography: A National Multicenter Trial

NCT ID: NCT01524029

Last Updated: 2012-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine the value of the new mammography technique called Digital Breast Tomosynthesis (DBT) compared to the current standard technique Digital Mammography for the early detection of Breast Cancer.

DBT is able to compute a three-dimensional image of a breast from several low-dose mammographies taken from different angles while the device is moving around the breast in a circular motion. This should overcome a significant limitation of Digital Mammography arising from the masking of breast cancer in a mammography image caused by overlying normal breast tissue.

This is a study conducted in several Austrian Breast Imaging Centers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective national multicenter multivendor trial aims at determining the impact of the novel technique Digital Breast Tomosynthesis (DBT) in the assessment and screening for breast cancer. Mammography is the primary imaging modality for the early detection of clinically occult breast cancer.

Despite advances in mammographic technique, mammography is still limited with regard to both sensitivity and specificity. In the majority of cases these limitations arise from the masking of subtle breast cancer lesions by overlapping breast tissue.

DBT is a novel technique that tries to overcome these limitations by performing a 3D-reconstruction of breast tissue from multiple low-dose digital mammographic images acquired in several planes in a 15 to 50 degree angle.

Early studies indicate an advantage of DBT compared to the standard Full Field Digital Mammography (FFDM) in terms of an improvement of specificity without cutback in sensitivity.

Controversy continues over the use of DBT in combination with FFDM or as a standalone screening method without concomitant 2D imaging. Unfortunately, the peer-reviewed publications evaluating DBT are limited and consist of single institution studies with a small number of participants.

The purpose of this study is to evaluate the novel technique of DBT compared to routine FFDM in a clinical large sample study (600 participants) to provide the path to implementation of this new technique into clinical and screening routine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast Cancer Screening Patients

Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site

No interventions assigned to this group

Diagnostic Patients

Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 25 years (40 years or older for Screening Cohort)
* No history of breast cancer
* Written informed consent
* Asymptomatic women in follow up for early detection of breast cancer or
* Patients with a recent positive mammography (BI-RADS 3-5)

Exclusion Criteria

* Pregnant and breast feeding women
* Unable to tolerate breast compression
* Breast implants
* Unable to understand or execute written informed consent
Minimum Eligible Age

25 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Thomas Moritz

Assistenzarzt

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Moritz, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Vienna

Thomas Helbich, MD Prof. MBA MSc

Role: STUDY_DIRECTOR

Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Graz

Graz, Styria, Austria

Site Status RECRUITING

Klinikum Wels-Grieskirchen

Wels, Upper Austria, Austria

Site Status RECRUITING

Medical University of Vienna

Vienna, , Austria

Site Status RECRUITING

Kaiser Franz Josef Spital

Vienna, , Austria

Site Status RECRUITING

Hanusch Krankenhaus

Vienna, , Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thomas Moritz, MD

Role: CONTACT

+43140400 ext. 4818

Thomas Helbich, Prof. MBA MSc

Role: CONTACT

+43140400 ext. 4818

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sabine Oswald, MD

Role: primary

+43 316385 ext. 13850

Stefan Meindl, MD

Role: primary

+437242415 ext. 2413

Thomas Moritz, MD

Role: primary

+43140400 ext. 4818

Gabrielle Kienzer, MD

Role: primary

+43160191 ext. 3608

Reinhard Bernt, MD

Role: primary

+43191021 ext. 86630

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TomoTrial001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tomosynthesis Mammographic Imaging Screening Trial
NCT02616432 ACTIVE_NOT_RECRUITING NA